← All trials
NCT05840341
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2023
- Primary completion
- Dec 30, 2025
- Completion date
- Dec 30, 2025
- First posted
- May 3, 2023
- Last posted
- May 3, 2023
- Enrollment
- 306
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Chinese Academy of Medical SciencesStudy chair
- Fudan UniversityReponsible party - principal investigator
- Fudan UniversityStudy director
- Shanghai University of Traditional Chinese MedicineStudy chair
- Fudan UniversitySponsor investigator
- Shanghai University of Traditional Chinese MedicineOfficial
- Fudan UniversityOfficial
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.